Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective
The DOI matches its Crossref record; 145 of the 146 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is a physiological incretin hormone from the lower gastrointestinal tract, partially explaining the augmented insulin response after oral compared to intravenous glucose administration in normal humans. In addition, GLP-1 also lowers glucagon concentrations, slows gastric emptying, stimulates (pro)insulin biosynthesis, and reduces food intake upon intracerebroventricular administration in animals. Therefore, GLP-1 offers some interesting perspective for the treatment of type 2, and perhaps also for type 1 diabetic patients. The other incretin hormone, gastric inhibitory polypeptide (GIP), has lost almost all its activity in type-2 diabetic patients. In contrast, GLP-1 glucose-dependently stimulates insulin secretion in type-2 diabetic patients and exogenous administration of GLP-1 ([7-37] or [7-36 amide]) in doses elevating plasma concentrations to approximately three to four times physiological postprandial levels fully normalizes fasting hyperglycaemia and reduces postprandial glycaemic increments. Due to rapid proteolytic cleavage, which results in an inactive or even antagonistic fragment. GLP-1 [9-36 amide], and to rapid elimination, the half-life of GLP-1 is too short to maintain therapeutic plasma levels for sufficient periods by subcutaneous injections of the natural peptide hormone. Current research aims to characterize GLP-1 analogues with more suitable pharmacokinetic properties than the original peptide. Given the large amount of GLP-1 present in L cells, it also appears worthwhile to search for more agents that could 'mobilize' this endogenous pool of GLP-1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1, a 30- or 31-amino-acid-long peptide hormone, is a gastrointestinal peptide secreted by the intestinal tract that potentiates insulin release and reduces glucagon’s concentration in physiological conditions (15, 16).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
In the citing paper
“Besides lowering blood glucose and reducing weight (incredibly visceral fat), GLP-1R agonists can also lower blood pressure, improve blood lipid disorder, and reduce fatty liver (16, 140).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [16]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationGastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 447
Talsania, T., Anini, Y., Siu, S., Drucker, D. J., & Brubaker, P. L. (2005) · Endocrinology · doi:10.1210/en.2005-0473 · Cited by 306
“agonist (24), the truncated form of PYY remains biologically”
BackgroundGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“Frontiers in Endocrinology 02 GLP-1, a 30- or 31-amino-acid-long peptide hormone, is a gastrointestinal peptide secreted by the intestinal tract that potentiates insulin release and reduces glucagon’s concentration in physiological conditions (15, 16).”
BackgroundWhat do we know about the secretion and degradation of incretin hormones?
Deacon, C. F. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.007 · Cited by 241
Metadata
- Authors
- Nauck, M. A.
- Affiliations
- Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
- Corresponding author
- Nauck, M. A.
- ORCID
- Nauck, M. A.
- Venue
- Acta Diabetologica
- Published
- 1998-10-23
- Volume
- 35
- Issue
- 3
- Pages
- 117-129
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W2079136334
- Cited by
- 94
- References
- 146
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 2 · 2021: 5 · 2020: 1 · 2019: 1 · 2017: 2 · 2015: 4 · 2014: 2 · 2013: 7 · 2012: 3
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, incretins, type 2 diabetes, type 1 diabetes, insulin secretion, glucose-dependent insulinotropic polypeptide, GLP-1 analogues, pharmacokinetics, gastric emptying, dietary intake, gastrointestinal hormones, L cells, fasting hyperglycemia, postprandial blood glucose
- MeSH terms
- Animals, Cerebral Ventricles, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Feeding Behavior, Gastric Emptying, Glucagon, Glucose, Humans, Insulin, Models, Biological, Peptide Fragments, Proinsulin, Protein Precursors, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.